Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike

Rhea-AI Filing Summary

Pliant Therapeutics director Gayle A. Crowell received a compensation grant of stock options. The award covers 70,000 options to buy Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.

According to the vesting schedule, 25% of the options vest on October 1, 2026, another 25% on January 1, 2027, and another 25% on April 1, 2027. The remaining 25% vest on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to Crowell’s continued service as a director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CROWELL GAYLE A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 70,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 70,000 options Exercise price: $1.14 per share Underlying shares: 70,000 shares +3 more

6 metrics

Options granted 70,000 options Stock Option (Right to Buy) grant to director Crowell

Exercise price $1.14 per share Exercise price for underlying common stock

Underlying shares 70,000 shares Common stock underlying the option award

Option expiration June 11, 2036 Expiration date of the stock options

First vesting date 25% on October 1, 2026 Initial tranche of options vesting

Subsequent vesting dates 25% on Jan 1, 2027; 25% on Apr 1, 2027 Intermediate vesting tranches

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price set at 1.1400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"25% of the shares subject to such option vest and become exercisable"

annual meeting of stockholders financial

"the next annual meeting of stockholders, subject to the Reporting Person's continued service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CROWELL GAYLE A

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.14	06/11/2026		A		70,000		(1)	06/11/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pliant Therapeutics (PLRX) director Gayle A. Crowell receive in this Form 4?

Gayle A. Crowell received a grant of 70,000 stock options as director compensation. These options allow her to buy Pliant Therapeutics common stock at a fixed price, subject to a multi-date vesting schedule and a long-term expiration date.

How many Pliant Therapeutics (PLRX) options were granted and at what exercise price?

The filing reports a grant of 70,000 stock options with an exercise price of $1.14 per share. This means Crowell can purchase up to 70,000 Pliant Therapeutics common shares at $1.14 once the options are vested and exercisable.

When do Gayle A. Crowell’s PLRX stock options start vesting?

The options vest in stages: 25% on October 1, 2026, 25% on January 1, 2027, and 25% on April 1, 2027. Vesting is conditioned on Crowell’s continued service to Pliant Therapeutics as a director through each vesting date mentioned.

What is the final vesting condition for the remaining PLRX options granted to Crowell?

The remaining 25% of the options vest on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders. This final portion also requires Crowell’s continued board service through that specified date.

When do Gayle A. Crowell’s Pliant Therapeutics options expire?

The granted stock options expire on June 11, 2036, according to the Form 4. After this expiration date, any unexercised options become worthless, so exercise must occur after vesting but before that 2036 expiration.

Did this PLRX Form 4 show any open-market buying or selling of shares?

The Form 4 reflects a grant of derivative securities, specifically stock options, coded as an acquisition award. It does not report any open-market purchases or sales of Pliant Therapeutics common stock by Gayle A. Crowell in this transaction.